Asahi Life Asset Management CO. LTD. Invests $440,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Asahi Life Asset Management CO. LTD. acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 1,600 shares of the biopharmaceutical company’s stock, valued at approximately $440,000.

Several other institutional investors have also added to or reduced their stakes in ALNY. Souders Financial Advisors raised its position in Alnylam Pharmaceuticals by 1.0% in the 2nd quarter. Souders Financial Advisors now owns 3,512 shares of the biopharmaceutical company’s stock valued at $853,000 after buying an additional 36 shares during the last quarter. V Square Quantitative Management LLC lifted its stake in Alnylam Pharmaceuticals by 21.9% in the second quarter. V Square Quantitative Management LLC now owns 334 shares of the biopharmaceutical company’s stock valued at $81,000 after acquiring an additional 60 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Alnylam Pharmaceuticals by 54.2% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 259 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 91 shares during the last quarter. Ashton Thomas Private Wealth LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth about $26,000. Finally, Daiwa Securities Group Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 1.1% in the 1st quarter. Daiwa Securities Group Inc. now owns 10,921 shares of the biopharmaceutical company’s stock valued at $1,632,000 after purchasing an additional 116 shares during the period. 92.97% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Raymond James increased their price target on Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Chardan Capital reiterated a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Barclays raised their target price on shares of Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. JPMorgan Chase & Co. boosted their price target on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a research note on Monday, August 26th. Finally, HC Wainwright restated a “buy” rating and set a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, October 18th. Six research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $290.86.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 15,148 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $270.00, for a total transaction of $4,089,960.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at approximately $19,829,070. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO Yvonne Greenstreet sold 15,148 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $270.00, for a total transaction of $4,089,960.00. Following the completion of the sale, the chief executive officer now owns 73,441 shares in the company, valued at approximately $19,829,070. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the sale, the director now directly owns 136 shares in the company, valued at approximately $35,632. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,398 shares of company stock worth $13,595,460 over the last quarter. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 1.4 %

Shares of ALNY traded up $3.91 during trading hours on Monday, reaching $288.77. The stock had a trading volume of 71,490 shares, compared to its average volume of 866,008. The firm has a 50-day simple moving average of $274.43 and a 200 day simple moving average of $222.40. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The company has a market capitalization of $36.53 billion, a price-to-earnings ratio of -106.29 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.61. The business had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. The firm’s quarterly revenue was up 107.0% on a year-over-year basis. During the same period last year, the business posted ($2.21) earnings per share. On average, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.